References
- Arrow K. Uncertainty and the welfare economics of medical care. Am Econ Rev 1963;53:941-73
- Phelps CE. Health economics, 3rd ed. Boston: Addison Wesley; 2003
- Brown M, ed. Integrated health care delivery: Theory, practice, evaluation, and prognosis. Gaithersburg, MD: Aspen Publishers, Inc.; 1996
- Gaynor M, Town RJ. Competition in health care markets, NBER Working Paper No. 17208. Cambridge, MA: NBER; 2011
- Neun SP, Santerre RE. Health economics: theories, insights, and industry studies, 4th ed. Mason: Thomson South-Western; 2007
- Organization for Economic Cooperation and Development (OECD). Competition and barriers to entry. Paris: OECD Headquarters; 2007
- United States House of Representatives, 114th Congress (2015). H.R. 6, An act to accelerate the discovery, development, and delivery of 21st century cures, and for other purposes; July 15, 2015
- United States Public Law 114-255 (Pub.L. 114–255). An Act to accelerate the discovery, development, and delivery of 21st century cures, and for other purposes; December 13, 2016
- Kaplan S. Winners and losers of the 21st Century Cures Act. STAT News; December 5, 2016. https://www.statnews.com/2016/12/05/21st-century-cures-act-winners-losers/ accessed January 3, 2017.
- Pear R. Cures Act gains bipartisan support that eluded Obama health law. The New York Times; December 8, 2016. http://www.nytimes.com/2016/12/08/us/politics/cures-act-health-care-congress.html accessed January 3, 2017
- Leonard K (2016). Latest Version of Drug and Device Overhaul Bill Doesn't Satisfy Critics. U.S. News & World Report; November 28. Available at: http://www.usnews.com/news/articles/2016-11-28/latest-version-of-21st-century-cures-act-doesnt-satisfy-critics accessed January 10, 2017.
- Fox M. Senate passes sweeping 21st Century Cures Act funding medicine; December 7, 2016. NBCnews.com accessed January 5, 2017
- Franz J. America’s new 21st Century Cures Act will speed up drug approvals. Is that a good thing? PRI; December 25, 2016. http://www.pri.org/stories/2016-12-25/americas-new-21st-century-cures-act-will-speed-drug-approvals-good-thing accessed January 8, 2017
- Mendoza RL. Pharmacoeconomics and clinical trials in multiple sclerosis: baseline data from the European Union. J Public Health 2014;22:211-8
- Avorn J Dangerous Deception – Hiding the Evidence of Adverse Drug Effects. N Engl J Med 2006;355:2169-71
- Brook RA. Specialty pharmaceuticals and the quest for better outcomes. J Med Econ 2016;19:63-9
- Fuller GN, Bone I. Disease modifying treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;71(Suppl 2):ii20-1
- Grant RW, Sugarman J. Ethics in human subjects research: do incentives matter? J Med Philosophy 2004;29:717-38
- Dal Bo P. Cooperation under the shadow of the future: Experimental evidence from infinitely repeated games. Am Econ Rev 2005;95:1591-1604
- Chang M. Monte Carlo simulation for the pharmaceutical industry: concepts, algorithms, and case studies. Boca Raton, FL: Taylor & Francis Group, LLC; 2010